

# Mohammad Mehdi Amiri

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4101777/publications.pdf>

Version: 2024-02-01

36  
papers

255  
citations

1039406

9  
h-index

1125271

13  
g-index

37  
all docs

37  
docs citations

37  
times ranked

284  
citing authors

#	ARTICLE	IF	CITATIONS
1	Immune function of plasmacytoid dendritic cells, natural killer cells, and their crosstalk in HBV infection. <i>Reviews in Medical Virology</i> , 2018, 28, e2007.	3.9	19
2	Monoclonal antibodies to various epitopes of hepatitis B surface antigen inhibit hepatitis B virus infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1083-1091.	1.4	17
3	Inhibition of tumor growth by mouse ROR1 specific antibody in a syngeneic mouse tumor model. <i>Immunology Letters</i> , 2018, 193, 35-41.	1.1	17
4	Localization of immunodominant epitopes within the B-determinant of hepatitis B surface antigen using monoclonal antibodies. <i>Archives of Virology</i> , 2016, 161, 2765-2772.	0.9	16
5	In vitro assessment of the effects of anti-HER2 monoclonal antibodies on proliferation of HER2-overexpressing breast cancer cells. <i>Immunotherapy</i> , 2014, 6, 43-49.	1.0	15
6	Integrational analysis of miRNAs data sets as a plausible missing linker between Epstein-Barr virus and vitamin D in relapsing remitting MS patients. <i>Gene</i> , 2019, 689, 1-10.	1.0	15
7	Epitope Mapping of Tetanus Toxin by Monoclonal Antibodies: Implication for Immunotherapy and Vaccine Design. <i>Neurotoxicity Research</i> , 2020, 37, 239-249.	1.3	15
8	A Novel Anti-HER2 Bispecific Antibody With Potent Tumor Inhibitory Effects In Vitro and In Vivo. <i>Frontiers in Immunology</i> , 2020, 11, 600883.	2.2	11
9	Construction and characterization of a new chimeric antibody against HER2. <i>Immunotherapy</i> , 2013, 5, 703-715.	1.0	10
10	Construction of a hepatitis B virus neutralizing chimeric monoclonal antibody recognizing escape mutants of the viral surface antigen (HBsAg). <i>Antiviral Research</i> , 2017, 144, 153-163.	1.9	10
11	Epitope Mapping of Human HER2 Specific Mouse Monoclonal Antibodies Using Recombinant Extracellular Subdomains. <i>Asian Pacific Journal of Cancer Prevention</i> , 2017, 18, 3103-3110.	0.5	9
12	Molecular Characterization of Murine Monoclonal Antibody Variable Regions Specific for Hepatitis B Surface Antigen. <i>Viral Immunology</i> , 2015, 28, 425-433.	0.6	8
13	Hersintuzumab: A novel humanized anti-HER2 monoclonal antibody induces potent tumor growth inhibition. <i>Investigational New Drugs</i> , 2018, 36, 171-186.	1.2	8
14	All-Trans-Retinoic Acid Differentially Regulates Proliferation of Normal and Leukemic B Cells From Different Subsets of Chronic Lymphocytic Leukemia. <i>Nutrition and Cancer</i> , 2015, 67, 285-291.	0.9	7
15	Illuminating the in vitro effects of Epstein-Barr virus and vitamin D on immune response in multiple sclerosis patients. <i>Journal of NeuroVirology</i> , 2021, 27, 260-271.	1.0	7
16	Epitope mapping of neutralising anti-SARS-CoV-2 monoclonal antibodies: Implications for immunotherapy and vaccine design. <i>Reviews in Medical Virology</i> , 2022, 32, e2347.	3.9	7
17	Identification of immunodominant epitopes on nucleocapsid and spike proteins of the SARS-CoV-2 in Iranian COVID-19 patients. <i>Pathogens and Disease</i> , 2022, 80, .	0.8	6
18	Production and characterization of recombinant human leukemia inhibitory factor and evaluation of anti-fertility effects of rabbit anti-rhLIF in Balb/c mice. <i>Protein Expression and Purification</i> , 2020, 174, 105684.	0.6	5

#	ARTICLE	IF	CITATIONS
19	Potent synergistic anti-tumor activity of a novel humanized anti-HER2 antibody hersintuzumab in combination with trastuzumab in xenograft models. <i>Investigational New Drugs</i> , 2021, 39, 697-704.	1.2	5
20	Influence of Pattern Recognition Receptor Ligands on Induction of Innate Immunity and Control of Hepatitis B Virus Infection. <i>Viral Immunology</i> , 2021, 34, 531-541.	0.6	5
21	All-trans retinoic acid in combination with sodium butyrate enhances specific monoclonal antibody productivity in recombinant CHO cell line. <i>Bioprocess and Biosystems Engineering</i> , 2018, 41, 961-971.	1.7	4
22	Antitumor effects of a recombinant baculovirus displaying anti-HER2 scFv expressing Apoptin in HER2 positive SK-BR-3 breast cancer cells. <i>Future Virology</i> , 2019, 14, 139-152.	0.9	4
23	Contribution of Fc fragment of monoclonal antibodies to tetanus toxin neutralization. <i>Neurotoxicity Research</i> , 2020, 37, 578-586.	1.3	4
24	Immunoreactivity pattern of monoclonal antibodies against Hepatitis B vaccine with global Hepatitis B virus genotypes. <i>Clinica Chimica Acta</i> , 2020, 510, 203-210.	0.5	4
25	A novel tumor inhibitory hybridoma monoclonal antibody with dual specificity for HER3 and HER2. <i>Current Research in Translational Medicine</i> , 2021, 69, 103277.	1.2	4
26	Differential Effects of Inhibitory and Stimulatory Anti-HER2 Monoclonal Antibodies on AKT/ERK Signaling Pathways. <i>Asian Pacific Journal of Cancer Prevention</i> , 2018, 19, 2255-2262.	0.5	4
27	Antibody response to HER2 extracellular domain and subdomains in mouse following DNA immunization. <i>Tumor Biology</i> , 2016, 37, 1217-1227.	0.8	3
28	Contraceptive and molecular function of a novel recombinant vaccine based human leukemia inhibitory factor on Balb/c mice: An experimental in vivo study. <i>Journal of Reproductive Immunology</i> , 2020, 142, 103195.	0.8	3
29	The Profile of Toll-like Receptor 2 (TLR2), TLR4 and Their Cytosolic Downstream Signaling Pathway in Common Variable Immunodeficiency (CVID) Patients. <i>Iranian Journal of Allergy, Asthma and Immunology</i> , 2018, 17, 188-200.	0.3	3
30	Differential Antibody Response to SARS-CoV-2 Antigens in Recovered and Deceased Iranian COVID-19 Patients. <i>Viral Immunology</i> , 2021, 34, 708-713.	0.6	2
31	Neutralization of tetanus toxin by a novel chimeric monoclonal antibody. <i>Toxicon</i> , 2021, 201, 27-36.	0.8	2
32	Inhibitory Effect of Polyclonal Antibodies Against HER3 Extracellular Subdomains on Breast Cancer Cell Lines. <i>Asian Pacific Journal of Cancer Prevention</i> , 2020, 21, 439-447.	0.5	2
33	Differential tumor inhibitory effects induced by HER3 extracellular subdomain-specific mouse monoclonal antibodies. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 347-361.	1.1	2
34	Development of a Novel Inhibitory Chimeric Anti-HER2 Monoclonal Antibody. <i>Iranian Journal of Immunology</i> , 2019, 16, 26-42.	0.4	1
35	Potent anti-tumor immune response and tumor growth inhibition induced by HER2 subdomain fusion protein in a mouse tumor model. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	1
36	Optimization of Expression and Purification of Recombinant Mouse plac1. <i>Avicenna Journal of Medical Biotechnology</i> , 2022, 14, 61-69.	0.2	0